Sunday, December 13, 2020

A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma

paythelady.61 shared this article with you from Inoreader

41416_2020_1180_Fig1_HTML.png

View on the web

No comments:

Post a Comment

Collaboration request

Hi there How would you like to earn a 35% commission for each sale for life by selling SEO services Every website owner requires the ...